ASP Isotopes recently released its latest Form 10-Q. The company describes itself as a development-stage advanced materials business focused on isotope production and related services in South Africa, Hong Kong and the United States. It operates through two segments: Nuclear Fuels, which is aimed at technologies for HALEU and Lithium-6, and Specialist Isotopes and Related Services, which targets higher-value isotopes used in nuclear medicine, semiconductors and other industrial applications.
In Item 2, Management’s Discussion and Analysis, ASP said it is still in the development and commercialization phase and had not generated revenue from sales of enriched isotopes as of June 30, 2026, despite beginning commercial production at both ASP enrichment facilities in Pretoria during the first half of 2025. The company said it is targeting initial commercial shipments of enriched C-14, Si-28 and Yb-176 in the second half of 2026, with C-14 and Si-28 tied to the ASP technology and Yb-176 tied to the QE laser-based facility.
ASP also said it has completed commissioning of its third enrichment facility, its first laser-based plant, and has started planning additional isotope plants in South Africa and other jurisdictions, including Iceland and the United States. The company said it is considering future development of ASP technology for Zinc-68, Xenon-129/136, Germanium-70/72/74 and Chlorine-37, and QE technology for Nickel-64, Gadolinium-160, Ytterbium-171, Lithium-6 and Lithium-7.
On the nuclear fuels side, ASP said its QLE subsidiary is pursuing U-235 enrichment in South Africa and has signed definitive agreements with TerraPower, including a term loan tied to construction of a uranium enrichment facility at Pelindaba and supply agreements for future HALEU deliveries. QLE also has a pre-implementation services contract with Necsa for facilities, infrastructure, utilities and services related to the proposed Pelindaba site.
The quarter’s strategic footprint was broadened by a January 2026 acquisition of Renergen, for which ASP issued 14,270,000 consideration shares. ASP described Renergen as South Africa’s onshore natural gas explorer and producer of LNG and liquid helium, with its Virginia Gas Project including LNG liquefaction, helium separation and helium liquefaction.
ASP also detailed a series of smaller acquisitions and investments in downstream medical isotope and radiopharmacy businesses. It said it owns 51% of PET Labs, acquired East Coast Nuclear Pharmacy in October 2025 for $2.5 million in total consideration, and acquired 60% of Numed Diagnostics in January 2026 for $0.8 million, with options to buy the remaining interests in both PET Labs and Numed.
The company said its board intends to separate the Nuclear Fuels business and the Specialist Isotopes and Related Services business into two independent companies. ASP said the planned separation would likely take the form of a listing of QLE as a separate public company, with a portion of QLE equity distributed to ASP stockholders, and that it continues to evaluate other separation options. As a result of these announcements, the company's shares have moved -0.23% on the market, and are now trading at a price of $4.27. For the full picture, make sure to review ASP Isotopes's 10-Q report.
